Transcriptomic Profiling Revealed Lnc-GOLGA6A-1 as a Novel Prognostic Biomarker of Meningioma Recurrence.
Journal
Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
received:
30
09
2021
accepted:
10
03
2022
pubmed:
14
5
2022
medline:
19
7
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
Meningioma is the most common primary central nervous system neoplasm, accounting for about a third of all brain tumors. Because their growth rates and prognosis cannot be accurately estimated, biomarkers that enable prediction of their biological behavior would be clinically beneficial. To identify coding and noncoding RNAs crucial in meningioma prognostication and pathogenesis. Total RNA was purified from formalin-fixed and paraffin-embedded tumor samples of 64 patients with meningioma with distinct clinical characteristics (16 recurrent, 30 nonrecurrent with follow-up of >5 years, and 18 with follow-up of <5 years without recurrence). Transcriptomic sequencing was performed using the HiSeq 2500 platform (Illumina), and biological and functional differences between meningiomas of different types were evaluated by analyzing differentially expression of messenger RNA (mRNA) and long noncoding RNA (IncRNA). The prognostic value of 11 differentially expressed RNAs was then validated in an independent cohort of 90 patients using reverse transcription quantitative (real-time) polymerase chain reaction. In total, 69 mRNAs and 108 lncRNAs exhibited significant differential expression between recurrent and nonrecurrent meningiomas. Differential expression was also observed with respect to sex (12 mRNAs and 59 lncRNAs), World Health Organization grade (58 mRNAs and 98 lncRNAs), and tumor histogenesis (79 mRNAs and 76 lncRNAs). Lnc-GOLGA6A-1, ISLR2, and AMH showed high prognostic power for predicting meningioma recurrence, while lnc-GOLGA6A-1 was the most significant factor for recurrence risk estimation (1/hazard ratio = 1.31; P = .002). Transcriptomic sequencing revealed specific gene expression signatures of various clinical subtypes of meningioma. Expression of the lnc-GOLGA61-1 transcript was found to be the most reliable predictor of meningioma recurrence.
Sections du résumé
BACKGROUND
Meningioma is the most common primary central nervous system neoplasm, accounting for about a third of all brain tumors. Because their growth rates and prognosis cannot be accurately estimated, biomarkers that enable prediction of their biological behavior would be clinically beneficial.
OBJECTIVE
To identify coding and noncoding RNAs crucial in meningioma prognostication and pathogenesis.
METHODS
Total RNA was purified from formalin-fixed and paraffin-embedded tumor samples of 64 patients with meningioma with distinct clinical characteristics (16 recurrent, 30 nonrecurrent with follow-up of >5 years, and 18 with follow-up of <5 years without recurrence). Transcriptomic sequencing was performed using the HiSeq 2500 platform (Illumina), and biological and functional differences between meningiomas of different types were evaluated by analyzing differentially expression of messenger RNA (mRNA) and long noncoding RNA (IncRNA). The prognostic value of 11 differentially expressed RNAs was then validated in an independent cohort of 90 patients using reverse transcription quantitative (real-time) polymerase chain reaction.
RESULTS
In total, 69 mRNAs and 108 lncRNAs exhibited significant differential expression between recurrent and nonrecurrent meningiomas. Differential expression was also observed with respect to sex (12 mRNAs and 59 lncRNAs), World Health Organization grade (58 mRNAs and 98 lncRNAs), and tumor histogenesis (79 mRNAs and 76 lncRNAs). Lnc-GOLGA6A-1, ISLR2, and AMH showed high prognostic power for predicting meningioma recurrence, while lnc-GOLGA6A-1 was the most significant factor for recurrence risk estimation (1/hazard ratio = 1.31; P = .002).
CONCLUSION
Transcriptomic sequencing revealed specific gene expression signatures of various clinical subtypes of meningioma. Expression of the lnc-GOLGA61-1 transcript was found to be the most reliable predictor of meningioma recurrence.
Identifiants
pubmed: 35551164
doi: 10.1227/neu.0000000000002026
pii: 00006123-202208000-00018
pmc: PMC9287111
doi:
Substances chimiques
RNA, Long Noncoding
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
360-369Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Congress of Neurological Surgeons.
Références
Kalamarides M, Stemmer-rachamimov A, Niwa-kawakita M, et al. Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene. 2011;30(20):2333-2344.
Korhonen K, Salminen T, Raitanen J, Auvinen A, Isola J, Haapasalo H. Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol. 2006;80(1):1-7.
Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015;122(1):4-23.
Rao A, Rajkumar T, Mani S. Perspectives of long non-coding RNAs in cancer. Mol Biol Rep An Int J Mol Cell Biol. 2017;44(2):203-218.
Quinn J, Chang H. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47-62.
Li Q, Jia H, Li H, et al. LncRNA and mRNA expression profiles of glioblastoma multiforme (GBM) reveal the potential roles of lncRNAs in GBM pathogenesis. Tumor Biol. 2016;37(11):14537-14552.
Li C, Wang Z, Zhang J, et al. Crosstalk of mRNA, miRNA, lncRNA, and circRNA and their regulatory pattern in pulmonary fibrosis. Mol Ther Nucleic Acids. 2019;18:204-218.
Slavik H, Balik V, Vrbkova J, et al. Identification of meningioma patients at high risk of tumor recurrence using MicroRNA profiling. Neurosurgery. 2020;87(5):1055-1063.
Szklarczyk D, Gable A, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-D613.
Thomas P, Campbell M, Kejariwal A, et al. Panther: a library of protein families and subfamilies indexed by function. Genome Res. 2003;13(9):2129-2141.
Thomas P, Kejariwal A, Guo N, et al. Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res. 2006;34(web server issue):W645-W650.
Bi W, Greenwald N, Mei Y, et al. Genomic landscape of high-grade meningiomas. npj Genomic Med. 2017;2(1):525-535.
Youngblood M, Miyagishima D, Jin L, et al. Associations of meningioma molecular subgroup and tumor recurrence. Neuro-oncology. 2020;23(5):783-794.
Papaioannou M, Djuric U, Kao J, et al. Proteomic analysis of meningiomas reveals clinically-distinct molecular patterns. Neuro-oncology. 2019;21(8):1028-1038.
Galani V, Lampri E, Varouktsi A, Alexiou G, Mitselou A, Kyritsis A. Genetic and epigenetic alterations in meningiomas. Clin Neurol Neurosurg. 2017;158:119-125.
Suppiah S, Nassiri F, Bi W, et al. Molecular and translational advances in meningiomas. Neuro-oncology. 2019;21(S1):4-17.
Li T, Ren J, Ma J, et al. LINC00702/miR-4652-3p/ZEB1 axis promotes the progression of malignant meningioma through activating Wnt/β-catenin pathway. Biomedicine. 2019;113(1):108718-108718.
Zhang Y, Yu R, Li Q, et al. SNHG1/miR-556-5p/TCF12 feedback loop enhances the tumorigenesis of meningioma through Wnt signaling pathway. J Cell Biochem. 2020;121(2):1880-1889.
Grenier J, Foureman P, Sloma E, Miller A. RNA-seq transcriptome analysis of formalin fixed, paraffin-embedded canine meningioma. PLoS One. 2017;12(10):e0187150.
Stranjalis G, Korfias S, Psachoulia C, et al. Serum S-100B as an indicator of early postoperative deterioration after meningioma surgery. Clin Chem. 2005;51(1):202-207.
Rombaut D, Chiu H, Decaesteker B, et al. Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes. Scientific Rep. 2019;9(1):5685.
Mock A, Geisenberger C, Orlik C, et al. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. Int J Cancer. 2016;139(2):424-425.
Jiang X, Iseki S, Maxson R, Sucov H, Morriss-kay G. Tissue origins and interactions in the mammalian skull vault. Developmental Biol. 2002;241(1):106-116.
Balik V. Histological structure of the major dural sinus walls in the posterior cranial fossa: a factor that might matter in dural sinus surgery. World Neurosurg. 2019;128:431-432.
Sade B, Chahlavi A, Krishnaney A, Nagel S, Choi E, Lee J. World Health Organization Grades II and III meningiomas are rare in the cranial base and spine. Neurosurgery. 2007;61(6):1194-1198.
Cornelius J, Slotty P, Steiger H, Hänggi D, Polivka M, George B. Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases. Acta Neurochirurgica. 2013;155(3):407-413.
McGovern S, Aldape K, Munsell M, Mahajan A, DeMonte F, Woo S. A comparison of World Health Organization tumor grades at recurrence in patients with non–skull base and skull base meningiomas. J Neurosurg. 2010;112(5):925-933.
Okano A, Miyawaki S, Hongo H, et al. Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges. Sci Rep. 2021;11(1):6987.
Maguire L, Thomas A, Goldstein A. Tumors of the neural crest: common themes in development and cancer. Dev Dyn. 2015;244(3):311-322.
Ostrom Q, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-oncology. 2014;16(4):iv1-63.
Clark V, Erson-omay E, Caglayan A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339(6123):1077-1080.
Sahm F, Schrimpf D, Stichel D, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017;18(5):682-694.